vs
Intellia Therapeutics, Inc.（NTLA）与REDWOOD TRUST INC（RWT）财务数据对比。点击上方公司名可切换其他公司
REDWOOD TRUST INC的季度营收约是Intellia Therapeutics, Inc.的1.1倍（$25.9M vs $23.0M），REDWOOD TRUST INC净利率更高（77.2% vs -416.2%，领先493.4%），Intellia Therapeutics, Inc.同比增速更快（78.8% vs -6.1%），过去两年Intellia Therapeutics, Inc.的营收复合增速更高（-10.8% vs -41.0%）
Intellia Therapeutics是美国临床阶段生物技术企业，专注于依托CRISPR技术开发具有潜在治愈效果的创新疗法。公司体内项目采用静脉注射CRISPR疗法，通过专属递送技术可在特定靶组织内精准编辑致病基因；体外项目则利用CRISPR改造细胞制备治疗产品，主攻未被满足的医疗需求。
Redwood Trust Inc是总部位于美国的专业房地产投资信托公司，主营住宅与商业抵押贷款、抵押贷款支持证券及房地产信贷类资产的投资管理，核心业务覆盖住宅抵押贷款发放、商业地产信贷和投资服务，客户以机构投资者和房地产市场参与者为主。
NTLA vs RWT — 直观对比
营收规模更大
RWT
是对方的1.1倍
$23.0M
营收增速更快
NTLA
高出84.9%
-6.1%
净利率更高
RWT
高出493.4%
-416.2%
两年增速更快
NTLA
近两年复合增速
-41.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $23.0M | $25.9M |
| 净利润 | $-95.8M | $20.0M |
| 毛利率 | — | — |
| 营业利润率 | -428.9% | — |
| 净利率 | -416.2% | 77.2% |
| 营收同比 | 78.8% | -6.1% |
| 净利润同比 | 25.7% | 402.6% |
| 每股收益（稀释后） | $-0.81 | $0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NTLARWT
| Q4 25 | $23.0M | $25.9M | ||
| Q3 25 | $13.8M | $15.0M | ||
| Q2 25 | $14.2M | $13.8M | ||
| Q1 25 | $16.6M | $27.9M | ||
| Q4 24 | $12.9M | $27.6M | ||
| Q3 24 | $9.1M | $25.5M | ||
| Q2 24 | $7.0M | $67.4M | ||
| Q1 24 | $28.9M | $74.5M |
净利润NTLARWT
| Q4 25 | $-95.8M | $20.0M | ||
| Q3 25 | $-101.3M | $-7.7M | ||
| Q2 25 | $-101.3M | $-98.5M | ||
| Q1 25 | $-114.3M | $16.1M | ||
| Q4 24 | $-128.9M | $-6.6M | ||
| Q3 24 | $-135.7M | $14.8M | ||
| Q2 24 | $-147.0M | $15.5M | ||
| Q1 24 | $-107.4M | $30.3M |
营业利润率NTLARWT
| Q4 25 | -428.9% | — | ||
| Q3 25 | -808.9% | -9.0% | ||
| Q2 25 | -772.2% | -679.0% | ||
| Q1 25 | -726.6% | 80.2% | ||
| Q4 24 | -1059.9% | -1.3% | ||
| Q3 24 | -1589.0% | 86.1% | ||
| Q2 24 | -1998.6% | 30.3% | ||
| Q1 24 | -394.0% | 41.3% |
净利率NTLARWT
| Q4 25 | -416.2% | 77.2% | ||
| Q3 25 | -735.2% | -51.4% | ||
| Q2 25 | -710.8% | -712.0% | ||
| Q1 25 | -687.6% | 57.8% | ||
| Q4 24 | -1001.2% | -24.0% | ||
| Q3 24 | -1489.5% | 58.1% | ||
| Q2 24 | -2112.6% | 23.0% | ||
| Q1 24 | -371.3% | 40.6% |
每股收益（稀释后）NTLARWT
| Q4 25 | $-0.81 | $0.11 | ||
| Q3 25 | $-0.92 | $-0.08 | ||
| Q2 25 | $-0.98 | $-0.76 | ||
| Q1 25 | $-1.10 | $0.10 | ||
| Q4 24 | $-1.27 | $-0.08 | ||
| Q3 24 | $-1.34 | $0.09 | ||
| Q2 24 | $-1.52 | $0.10 | ||
| Q1 24 | $-1.12 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $449.9M | $255.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $671.4M | $982.6M |
| 总资产 | $842.1M | $23.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NTLARWT
| Q4 25 | $449.9M | $255.7M | ||
| Q3 25 | $511.0M | $226.3M | ||
| Q2 25 | $459.7M | $302.0M | ||
| Q1 25 | $503.7M | $259.9M | ||
| Q4 24 | $601.5M | $245.2M | ||
| Q3 24 | $658.1M | $253.7M | ||
| Q2 24 | $691.1M | $275.6M | ||
| Q1 24 | $791.3M | $275.4M |
总债务NTLARWT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $1.7B |
股东权益NTLARWT
| Q4 25 | $671.4M | $982.6M | ||
| Q3 25 | $748.4M | $999.0M | ||
| Q2 25 | $715.3M | $1.1B | ||
| Q1 25 | $779.9M | $1.2B | ||
| Q4 24 | $872.0M | $1.2B | ||
| Q3 24 | $962.6M | $1.2B | ||
| Q2 24 | $971.1M | $1.2B | ||
| Q1 24 | $1.0B | $1.2B |
总资产NTLARWT
| Q4 25 | $842.1M | $23.7B | ||
| Q3 25 | $925.3M | $22.6B | ||
| Q2 25 | $898.9M | $21.3B | ||
| Q1 25 | $986.2M | $19.9B | ||
| Q4 24 | $1.2B | $18.3B | ||
| Q3 24 | $1.2B | $18.4B | ||
| Q2 24 | $1.2B | $16.5B | ||
| Q1 24 | $1.3B | $15.1B |
负债/权益比NTLARWT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 1.39× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-69.3M | $-10.1B |
| 自由现金流经营现金流 - 资本支出 | $-69.4M | — |
| 自由现金流率自由现金流/营收 | -301.6% | — |
| 资本支出强度资本支出/营收 | 0.5% | — |
| 现金转化率经营现金流/净利润 | — | -504.15× |
| 过去12个月自由现金流最近4个季度 | $-395.9M | — |
8季度趋势，按日历期对齐
经营现金流NTLARWT
| Q4 25 | $-69.3M | $-10.1B | ||
| Q3 25 | $-76.9M | $-2.7B | ||
| Q2 25 | $-99.6M | $-2.1B | ||
| Q1 25 | $-148.9M | $-2.0B | ||
| Q4 24 | $-85.2M | $-5.9B | ||
| Q3 24 | $-84.8M | $-2.1B | ||
| Q2 24 | $-58.2M | $-2.0B | ||
| Q1 24 | $-120.7M | $-954.2M |
自由现金流NTLARWT
| Q4 25 | $-69.4M | — | ||
| Q3 25 | $-76.9M | — | ||
| Q2 25 | $-99.9M | — | ||
| Q1 25 | $-149.7M | — | ||
| Q4 24 | $-86.2M | — | ||
| Q3 24 | $-86.1M | — | ||
| Q2 24 | $-59.2M | — | ||
| Q1 24 | $-123.2M | — |
自由现金流率NTLARWT
| Q4 25 | -301.6% | — | ||
| Q3 25 | -558.2% | — | ||
| Q2 25 | -701.0% | — | ||
| Q1 25 | -900.1% | — | ||
| Q4 24 | -669.4% | — | ||
| Q3 24 | -945.2% | — | ||
| Q2 24 | -850.9% | — | ||
| Q1 24 | -425.7% | — |
资本支出强度NTLARWT
| Q4 25 | 0.5% | — | ||
| Q3 25 | 0.2% | — | ||
| Q2 25 | 1.7% | — | ||
| Q1 25 | 4.4% | — | ||
| Q4 24 | 7.6% | — | ||
| Q3 24 | 14.0% | — | ||
| Q2 24 | 14.5% | — | ||
| Q1 24 | 8.7% | — |
现金转化率NTLARWT
| Q4 25 | — | -504.15× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -120.92× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -140.86× | ||
| Q2 24 | — | -126.56× | ||
| Q1 24 | — | -31.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
RWT
暂无分部数据
